Business Wire

Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today

Share

Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005819/en/

The publication marks a clear consensus on allergen immunotherapy (AIT). It was co-authored by 49 world-renowned allergy specialists from 40 countries and coordinated by Professor Giorgio Walter Canonica, Personalised Medicine, Asthma and Allergy, Humanitas University and Research (Milano, Italy) and Professor Cristoforo Incorvaia, Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, (Milano, Italy), with an unrestricted grant from Stallergenes Greer.

The article demonstrates that there is very strong evidence to show that AIT achieves its primary therapeutic goals in patients with respiratory allergies1,2 by reducing the frequency and intensity of symptoms, the use of rescue medications, and improving quality of life for people with allergies.

Personalised medicine is improving the effectiveness and precision of allergy diagnosis and consequently increasing the performance and treatment outcome of AIT.

This landmark publication, which is fully aligned with Stallergenes Greer’s commitment, highlights the unique role of AIT in allergy treatment encompassing the prediction of a successful treatment, the potential prevention or progression of an allergic disease, and the possibility of providing such advances at affordable costs,” states Amer Jaber, EVP Operations Europe and President of Stallergenes SAS, who heads Stallergenes Greer's R&D.

AIT: a medical model of personalised healthcare

The article outlines that personalised allergy care is valuable and may also be preventive by focusing on quality of life, predictive by allowing treatment to be adjusted to the individual’s response and participative by empowering the patient.

AIT is consistent with the three major needs to be met in personalised medicine:
- the identification of the molecular mechanism of the disease,
- the availability of diagnostic tools to recognise this mechanism, and
- the availability of a treatment capable of blocking the mechanism3,4.

AIT delivers customised healthcare, with medical decisions, practices, and/or products tailored to the individual patient5.

Leveraging precision medicine for personalised allergy care

This tailor-made approach to diagnosis, decision-making, product choice and treatment schedules may enhance effectiveness, minimise adverse events, improve quality of life and reduce the socio-economic impact of allergies 6,7,8,9.

Stallergenes Greer’s purpose “Enabling precision medicine to improve life for people with allergies” is in line with the statements set out in the article. Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to maximise treatment outcomes for patients with allergies.

Read the full article here: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14575

ABOUT STALLERGENES GREER Ltd

Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Additional information is available at: https://www.stallergenesgreer.com/


1 Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
2 Demoly P, et al. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):640-648.
3 Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010: 22; 363(4):301-4.
4 Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy. 2015: 8;13:24.
5 Canonica GW, et al. Allergen Immunotherapy (AIT): A prototype of precision medicine. World Allergy Organ J. 2015;8 (1), 31 2015.
6 Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016; 137:545-558.
7 Caillot N, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. J Allergy Clin Immunol. 2017;140; 759-770.
8 Gueguen C, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. Allergy. 2019; 74:2223-2226.
9 Luce S, et al. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy. Allergy. 2020; 75:1513-1516.

Contact information

Communications
Catherine Kress
Tel: +33 01 55 59 26 05
Email: catherine.kress@stallergenesgreer.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Health Professionals Petition WHO for Guidance: People Should Use Nasal Sprays to Combat COVID-19 Pandemic; Doctors Use in Treating Patients25.1.2021 09:00:00 CETPress release

Today, a consortium of health professionals petitioned the World Health Organization to issue Guidance calling on: all people to use nasal sprays to combat the COVID-19 pandemic; doctors to use them in treating COVID-19 patients; and, Member-States to implement public health policies promoting the use of nasal sprays to both prevent and treat COVID-19. The petition asks the WHO to promulgate guidance that promotes the use of nasal sprays with data indicating that they are antiviral (blocks viral adhesion), virucidal (kills or deactivates the virus), anti-bacterial (block bacteria, in particular pneumonia bacteria) and bactericidal (kills bacteria, in particular pneumonia bacteria). “We have data showing that certain nasal sprays don’t just wash away the virus. Certain sprays actually block, deactivate and/or kill the virus,” said Dr. Gustavo Ferrer, a respiratory illness expert who has conducted research on the use of nasal sprays to combat COVID-19, and is among the petitioners. As a

OpenGate Capital Portfolio Company SMAC Signs Agreement to Sell Skylights Business to Kingspan Light + Air25.1.2021 09:00:00 CETPress release

OpenGate Capital, a global private equity firm, announced today that its portfolio company, SMAC, has reached an agreement to sell its skylights division to Kingspan Light + Air, a division of Kingspan Group Plc (ISEQ: KRX and LSE: KGP). The agreement includes the sale of Skydôme, a subsidiary focused on the production of daylighting, ventilation, smoke evacuation, and roofing access systems, and Essemes Services, a division of Skydôme, specializing in the installation of skylights and the maintenance of fire safety equipment. Terms of the agreement were not disclosed, and the final sale is subject to closing conditions and works council consultation. The pending sale of Skydôme and Essemes enables SMAC to focus on its core Travaux business, which provides waterproofing and building envelope solutions. This announcement follows the previous agreement to sell SMAC’s AXTER Membranes division which is targeted to close in 2021. OpenGate acquired SMAC from Colas Group in May of 2019. Andre

Mitsui Mining & Smelting Co., Ltd. to Initiate Mass Production of HRDP ® , a Special Glass Carrier for Next-Generation Semiconductor Packaging Devices25.1.2021 07:00:00 CETPress release

For the commercialization of HRDP®1, a special glass carrier for the next-generation semiconductor packaging devices, Mitsui Mining & Smelting Co., Ltd. (President: Keiji Nishida; hereinafter, “Mitsui Kinzoku”) has been expanding the establishment of a system for mass production in collaboration with GEOMATEC Co., Ltd. (President: Kentaro Matsuzaki). Mitsui Kinzoku is pleased to announce today that mass production of HRDP® has started for a domestic multi-chip module manufacturer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210124005060/en/ Exterior photograph of HRDP®, in the 12-inch wafer type (Photo: Business Wire) In its January 2018 news release, Mitsui Kinzoku announced the development of HRDP®, a material for the creation of ultra-fine circuits using a glass carrier for the Fan Out panel level package, based on the RDL First method2. HRDP® is a special glass carrier capable of achieving high production efficiency o

Alaska Cargo and Cold Storage Launches Major Addition to the Global Cold Chain25.1.2021 06:01:00 CETPress release

Alaska Cargo and Cold Storage, LLC (ACCS) and the State of Alaska executed a 55-year lease agreement at Ted Stevens Anchorage International Airport (ANC), marking a major milestone in the development of a more than 700,000-square-foot, climate-controlled warehouse facility. With 32.5 million cubic feet of capacity, the facility will provide ANC with a critical piece of infrastructure at the world’s sixth-busiest cargo airport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210124005094/en/ Alaska Cargo and Cold Storage, LLC signed a 55-year ground lease with the State of Alaska for a 700,000-square-foot cold storage facility strategically located at Ted Stevens Anchorage International Airport, the sixth-busiest cargo airport in the world. (Photo: Ted Stevens Anchorage International Airport) “This project will improve shipping to and through Anchorage, create jobs, and show the world that Alaska is open for business,” said Al

Takeda Named Global Top Employer for Fourth Consecutive Year25.1.2021 01:00:00 CETPress release

Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company’s commitment to creating an exceptional people experience for its global workforce. For more than 30 years, Top Employers Institute has given annual award certification to companies with outstanding culture, work environments, benefits and opportunities for their people. The Institute certifies organizations based on the results of its HR Best Practices Survey. The survey covers 20 people-centric topic areas, including Career Development, Culture, Diversity & Inclusion, Learning, Sustainability, Values, Well-being and Work Environment. “We are very proud of the global, regional and country recognition we’ve received from Top E

GPD Companies, Inc. to Acquire Distrupol22.1.2021 14:33:00 CETPress release

GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0

Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 12:50:00 CETPress release

Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2020Sept. 30, 2020Dec. 31, 2019SequentialYear-on-yearRevenue $5,532 $5,258 $8,228 5% -33%Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4%Net income (loss) - GAAP basis $374 $(82) $333 n/m 12%Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33%Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bpsPretax segment operating income* $654 $575 $1,006 14% -35%Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bpsNet income, excluding charges & credits* $309 $228 $545 35% -43%Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26%North America 1,167 1,034 2,339 13% -50%Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -33% *These are non-

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom